Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pediatric phase 3 study of intravenous anifrolumab in active systemic lupus erythematosus
ChiCTR2400085601Phase 3Not yet recruiting
- Sponsor
- Peking Union Medical College Hospital
- Start
- Jun 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of anifrolumab in systemic lupus erythematosus (SLE) (4 arms), sponsored by Peking Union Medical College Hospital. Primary endpoints: Pharmacokinetics and BICLA response. Planned start Jun 2024; status: not yet recruiting.
02
Drugs
anifrolumab
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on ChiCTR2400085601.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400085601.